JP2002526454A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002526454A5 JP2002526454A5 JP2000573758A JP2000573758A JP2002526454A5 JP 2002526454 A5 JP2002526454 A5 JP 2002526454A5 JP 2000573758 A JP2000573758 A JP 2000573758A JP 2000573758 A JP2000573758 A JP 2000573758A JP 2002526454 A5 JP2002526454 A5 JP 2002526454A5
- Authority
- JP
- Japan
- Prior art keywords
- glp
- serine
- alanine
- glutamine
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 28
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 18
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 15
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 15
- 235000004400 serine Nutrition 0.000 description 15
- 229960001153 serine Drugs 0.000 description 15
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 14
- 235000004279 alanine Nutrition 0.000 description 14
- 239000004471 Glycine Substances 0.000 description 13
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 13
- 235000004554 glutamine Nutrition 0.000 description 13
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 13
- 229960002743 glutamine Drugs 0.000 description 13
- 229960002449 glycine Drugs 0.000 description 13
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 12
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 11
- 235000018417 cysteine Nutrition 0.000 description 11
- 229960002433 cysteine Drugs 0.000 description 11
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 11
- 235000002374 tyrosine Nutrition 0.000 description 11
- 229960004441 tyrosine Drugs 0.000 description 11
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 11
- 235000014393 valine Nutrition 0.000 description 11
- 229960004295 valine Drugs 0.000 description 11
- 239000004474 valine Substances 0.000 description 11
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 10
- 229960003767 alanine Drugs 0.000 description 10
- 239000004475 Arginine Substances 0.000 description 9
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 9
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 9
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 9
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 9
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
- 239000004472 Lysine Substances 0.000 description 9
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 9
- 239000004473 Threonine Substances 0.000 description 9
- 235000009697 arginine Nutrition 0.000 description 9
- 229960003121 arginine Drugs 0.000 description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 9
- 235000009582 asparagine Nutrition 0.000 description 9
- 229960001230 asparagine Drugs 0.000 description 9
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 9
- 235000014705 isoleucine Nutrition 0.000 description 9
- 229960000310 isoleucine Drugs 0.000 description 9
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 9
- 235000005772 leucine Nutrition 0.000 description 9
- 229960003136 leucine Drugs 0.000 description 9
- 235000018977 lysine Nutrition 0.000 description 9
- 229960003646 lysine Drugs 0.000 description 9
- 235000006109 methionine Nutrition 0.000 description 9
- 229930182817 methionine Natural products 0.000 description 9
- 229960004452 methionine Drugs 0.000 description 9
- 235000008521 threonine Nutrition 0.000 description 9
- 229960002898 threonine Drugs 0.000 description 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 235000008729 phenylalanine Nutrition 0.000 description 8
- 229960005190 phenylalanine Drugs 0.000 description 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 8
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 7
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 7
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 6
- 235000003704 aspartic acid Nutrition 0.000 description 6
- 229960005261 aspartic acid Drugs 0.000 description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
- 235000013922 glutamic acid Nutrition 0.000 description 6
- 239000004220 glutamic acid Substances 0.000 description 6
- 229960002885 histidine Drugs 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
- NGJOFQZEYQGZMB-KTKZVXAJSA-N (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NGJOFQZEYQGZMB-KTKZVXAJSA-N 0.000 description 3
- 101800004295 Glucagon-like peptide 1(7-36) Proteins 0.000 description 3
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 3
- 150000001408 amides Chemical group 0.000 description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 3
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 2
- 229930028154 D-arginine Natural products 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 230000002473 insulinotropic effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002333 glycines Chemical group 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10171998P | 1998-09-24 | 1998-09-24 | |
| US60/101,719 | 1998-09-24 | ||
| PCT/US1999/022026 WO2000016797A2 (en) | 1998-09-24 | 1999-09-22 | Use of glp-1 or analogs in treatment of stroke |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002526454A JP2002526454A (ja) | 2002-08-20 |
| JP2002526454A5 true JP2002526454A5 (https=) | 2006-11-24 |
Family
ID=22286048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000573758A Pending JP2002526454A (ja) | 1998-09-24 | 1999-09-22 | 卒中の治療におけるｇｌｐ−１または類似体の使用 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1115421B1 (https=) |
| JP (1) | JP2002526454A (https=) |
| CN (1) | CN1163267C (https=) |
| AT (1) | ATE433324T1 (https=) |
| AU (1) | AU766375B2 (https=) |
| BR (1) | BR9913932A (https=) |
| CA (1) | CA2344056A1 (https=) |
| DE (1) | DE69940975D1 (https=) |
| ES (1) | ES2325777T3 (https=) |
| MY (1) | MY155270A (https=) |
| TW (1) | TWI260986B (https=) |
| WO (1) | WO2000016797A2 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
| US6429197B1 (en) | 1998-10-08 | 2002-08-06 | Bionebraska, Inc. | Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
| US7259136B2 (en) | 1999-04-30 | 2007-08-21 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating peripheral vascular disease |
| EP2213743A1 (en) | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| JP2003532691A (ja) * | 2000-05-05 | 2003-11-05 | ノボ ノルディスク アクティーゼルスカブ | 重症疾患神経障害 |
| CN103356996A (zh) | 2000-05-19 | 2013-10-23 | 埃米林药品公司 | Glp-1用于制备治疗急性冠脉综合征的药物的用途 |
| ATE408414T1 (de) | 2001-07-31 | 2008-10-15 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
| CN1561224A (zh) * | 2001-10-01 | 2005-01-05 | 伊莱利利公司 | 降低与严重疾病相关的死亡率和发病率的方法 |
| AU2002364586A1 (en) | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| WO2005003296A2 (en) | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20030199445A1 (en) | 2002-02-07 | 2003-10-23 | Knudsen Lotte Bjerre | Use of GLP-1 compound for treatment of critically ill patients |
| PL209734B1 (pl) | 2002-02-20 | 2011-10-31 | Emisphere Tech Inc | Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie |
| DK1641823T3 (da) | 2003-06-12 | 2011-12-12 | Lilly Co Eli | GLP-1-analog fusionsproteiner |
| ATE461217T1 (de) | 2003-12-18 | 2010-04-15 | Novo Nordisk As | Glp-1-verbindungen |
| US20060286129A1 (en) | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
| HUE027902T2 (en) | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
| CA2608311C (en) | 2005-05-13 | 2012-11-27 | Eli Lilly And Company | Glp-1 pegylated compounds |
| CN101258163B (zh) | 2005-06-30 | 2013-08-21 | 益普生制药股份有限公司 | Glp-1药物组合物 |
| US8765669B2 (en) | 2008-06-17 | 2014-07-01 | Glytech, Inc. | Glycosylated GLP-1 peptide |
| EP2216042A1 (en) | 2009-02-09 | 2010-08-11 | Ipsen Pharma S.A.S. | GLP-1 analogues pharmaceutical compositions |
| US8614185B2 (en) | 2009-05-04 | 2013-12-24 | Centocor Ortho Biotech Inc. | Fusion proteins of alpha-MSH derivatives and Fc |
| WO2010129248A1 (en) | 2009-05-06 | 2010-11-11 | Centocor Ortho Biotech Inc. | Melanocortin receptor binding conjugates |
| KR20120101037A (ko) | 2009-10-30 | 2012-09-12 | 오츠카 가가쿠 가부시키가이샤 | 항원성 ｇｌｐ?１ 아날로그의 당쇄 부가체 |
| JP6006118B2 (ja) | 2009-12-16 | 2016-10-12 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アナログ及び誘導体 |
| JP2013530993A (ja) | 2010-07-02 | 2013-08-01 | アンジオケム インコーポレーテッド | 治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用 |
| JP6039569B2 (ja) * | 2010-11-09 | 2016-12-07 | ノヴォ ノルディスク アー／エス | 二重アシル化されたｇｌｐ−１誘導体 |
| SI2651398T1 (en) | 2010-12-16 | 2018-04-30 | Novo Nordisk A/S | SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS |
| PL2696687T3 (pl) | 2011-04-12 | 2017-06-30 | Novo Nordisk A/S | Pochodne podwójnie acylowanej GLP-1 |
| PT2827845T (pt) | 2012-03-22 | 2019-03-29 | Novo Nordisk As | Composições compreendendo um agente de entrega e sua preparação |
| HRP20181447T1 (hr) | 2012-03-22 | 2018-11-02 | Novo Nordisk A/S | Pripravci glp-1 peptida i njihova priprava |
| JP6517690B2 (ja) | 2012-06-20 | 2019-05-22 | ノヴォ ノルディスク アー／エス | ペプチド及び送達剤を含む錠剤製剤 |
| KR102272671B1 (ko) | 2013-05-02 | 2021-07-06 | 노보 노르디스크 에이/에스 | Glp-1 화합물의 경구 투여 |
| US20160122406A1 (en) * | 2013-06-07 | 2016-05-05 | The Administrators Of The Tulane Educational Fund | Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| KR101825048B1 (ko) | 2014-12-31 | 2018-02-05 | 주식회사 제넥신 | GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도 |
| PT3257524T (pt) | 2015-02-11 | 2020-11-27 | Gmax Biopharm Llc | Preparação de solução estabilizada de proteína de fusão de anticorpo glp-1r farmacêutica |
| CN105254720B (zh) * | 2015-11-18 | 2018-10-09 | 暨南大学 | 一种多受体激动剂po13及应用 |
| WO2018113340A1 (zh) * | 2016-12-20 | 2018-06-28 | 中国药科大学 | 多肽p11及其用途 |
| JP6898518B2 (ja) | 2018-02-02 | 2021-07-07 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物 |
| CN117126279A (zh) | 2018-03-20 | 2023-11-28 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| CN112521501A (zh) | 2019-09-18 | 2021-03-19 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| CN115397455A (zh) * | 2020-01-16 | 2022-11-25 | 上海仁会生物制药股份有限公司 | Glp-1给药方案 |
| US20240050531A1 (en) * | 2020-12-16 | 2024-02-15 | The Chinese University Of Hong Kong | A method for reversing aging brain functional decline |
| CN116970062B (zh) * | 2022-04-29 | 2024-04-09 | 南京知和医药科技有限公司 | 一种超长效glp-1多肽衍生物及其制备方法和用途 |
| CN119909159A (zh) * | 2022-06-23 | 2025-05-02 | 广州银诺医药集团股份有限公司 | 一种改进的glp-1受体激动剂的融合蛋白在治疗疾病中的用途 |
| CN119744271A (zh) | 2022-09-08 | 2025-04-01 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与fgf21的融合蛋白，以及其药物组合物和应用 |
| CN119569847A (zh) * | 2024-12-03 | 2025-03-07 | 中国科学院上海有机化学研究所 | Glp-1变体及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK36392D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
| US6277819B1 (en) * | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| IL128332A0 (en) * | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| US6006753A (en) * | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| EP1049486A4 (en) * | 1997-12-05 | 2006-01-04 | Lilly Co Eli | GLP-1 FORMULATIONS |
-
1999
- 1999-09-21 MY MYPI99004103A patent/MY155270A/en unknown
- 1999-09-22 DE DE69940975T patent/DE69940975D1/de not_active Expired - Lifetime
- 1999-09-22 EP EP99951570A patent/EP1115421B1/en not_active Expired - Lifetime
- 1999-09-22 ES ES99951570T patent/ES2325777T3/es not_active Expired - Lifetime
- 1999-09-22 JP JP2000573758A patent/JP2002526454A/ja active Pending
- 1999-09-22 BR BR9913932-4A patent/BR9913932A/pt not_active Application Discontinuation
- 1999-09-22 CA CA002344056A patent/CA2344056A1/en not_active Abandoned
- 1999-09-22 AU AU63985/99A patent/AU766375B2/en not_active Ceased
- 1999-09-22 CN CNB998113077A patent/CN1163267C/zh not_active Expired - Fee Related
- 1999-09-22 AT AT99951570T patent/ATE433324T1/de not_active IP Right Cessation
- 1999-09-22 WO PCT/US1999/022026 patent/WO2000016797A2/en not_active Ceased
- 1999-10-20 TW TW088116396A patent/TWI260986B/zh not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002526454A5 (https=) | ||
| JP2002523466A5 (https=) | ||
| JP2004504406A5 (https=) | ||
| CA2473340C (en) | Formulations comprising a glp-1 compound and a delivery agent, and uses thereof | |
| ES2359031T3 (es) | Composición farmacéutica que comprende un péptido de exendina-4. | |
| EP1140148B1 (en) | Shelf-stable solution formulation of glucagon-like peptide-1 | |
| ES2325777T3 (es) | Uso de glp-1 o analogos en el tratamiento de accidente cerebrovascular. | |
| CA2271169A1 (en) | Use of glp-1 analogs and derivatives administered peripherally in regulation of obesity | |
| JP2005530732A5 (https=) | ||
| JP2020073481A5 (https=) | ||
| PT1143989E (pt) | Exendinas para supressão de glucagon | |
| TWI633887B (zh) | 用於預防及／或治療多囊性腎臟病之藥物 | |
| JP2006514104A5 (https=) | ||
| JP2010502734A5 (https=) | ||
| FI4267105T3 (fi) | Vasta-ainekoostumuksia ja niiden käyttömenetelmiä | |
| JP2001525371A (ja) | Ｇｌｐ−１製剤 | |
| JPH10500696A (ja) | グルカゴンを含んでなる医薬製剤 | |
| JP2004505095A5 (https=) | ||
| JP2023512501A5 (https=) | ||
| WO2002015903A3 (de) | Neue pharmazeutische zusammensetzung zur verabreichung von n-0923 | |
| JP2007504178A5 (https=) | ||
| JP2016501204A5 (https=) | ||
| JP2002534450A5 (https=) | ||
| NZ552558A (en) | Compositions for delivering peptide YY and PYY agonists | |
| JP2011526886A5 (https=) |